Analyzing Cost of Revenue: Eli Lilly and Company and GSK plc

Cost Dynamics: Eli Lilly vs. GSK (2014-2023)

__timestamp	Eli Lilly and Company	GSK plc
Wednesday, January 1, 2014	4932500000	7323000000
Thursday, January 1, 2015	5037200000	8853000000
Friday, January 1, 2016	5654900000	9290000000
Sunday, January 1, 2017	6070200000	10342000000
Monday, January 1, 2018	4681700000	10241000000
Tuesday, January 1, 2019	4721200000	11863000000
Wednesday, January 1, 2020	5483300000	11704000000
Friday, January 1, 2021	7312800000	11603000000
Saturday, January 1, 2022	6629800000	9554000000
Sunday, January 1, 2023	7082200000	8565000000

Igniting the spark of knowledge

Analyzing Cost of Revenue: Eli Lilly and Company vs. GSK plc

In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for two giants: Eli Lilly and Company and GSK plc, from 2014 to 2023. Over this period, GSK consistently reported higher costs, peaking in 2019 with a 62% increase from 2014. Meanwhile, Eli Lilly's cost of revenue saw a notable rise, particularly in 2021, marking a 48% increase from its 2014 figures. The data reveals a strategic shift in cost management, with Eli Lilly showing a more volatile pattern compared to GSK's steady climb. This insight into cost dynamics not only highlights the operational strategies of these companies but also provides a window into the broader economic factors influencing the pharmaceutical sector.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025